Free Trial

Evan Seigerman Analyst Performance

Analyst at BMO Capital Markets

Evan Seigerman is a stock analyst at BMO Capital Markets in the medical sector, covering 12 publicly traded companies. Over the past year, Evan Seigerman has issued 7 stock ratings, including buy, hold, and sell recommendations. While full access to Evan Seigerman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan Seigerman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
44 Last 6 Years
Buy Recommendations
47.62% 20 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy47.6%20 ratings
Hold40.5%17 ratings
Sell11.9%5 ratings

Out of 42 total stock ratings issued by Evan Seigerman at BMO Capital Markets, the majority (47.6%) have been Buy recommendations, followed by 40.5% Hold and 11.9% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
91.7% of companies on NASDAQ
11 companies
NYSE
8.3% of companies on NYSE
1 company

Evan Seigerman, an analyst at BMO Capital Markets, currently covers 12 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
100.0%

Evan Seigerman of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
58.3%
PHARMACEUTICAL PREPARATIONS
3 companies
25.0%
LARGE CAP PHARMA
1 company
8.3%
MED - DRUGS
1 company
8.3%

Evan Seigerman's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
10/14/2025Reiterated Rating$57.51$55.00Market Perform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/5/2025Set Price Target$472.27$530.00Outperform
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Reiterated Rating$78.05$60.00Underperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
5/12/2025Boost Price Target$47.07$120.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
5/6/2025Boost Price Target$125.03$115.00Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/12/2025Boost Price Target$103.85$115.00Outperform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/31/2025Set Price Target$484.24$545.00